AstraZeneca’s Bevespi Aerosphere was shown to improve lung function in patients with moderate- to very severe-chronic obstructive pulmonary disease (COPD), in the latest PINNACLE 4 clinical trial. The promising results pave the way for regulatory approval in Europe and Asia. Bevespi Aerosphere combines two bronchodilators, glycopyrronium (long-acting…
Stem cells offer protective effects for damaged lung cells exposed to cigarette smoking by alleviating oxidative stress in mitochondria, a study shows. These results were also observed in mice and suggest a potential new therapeutic strategy for oxidative stress-dependent lung diseases, such as chronic obstructive pulmonary disease (COPD). The study…
Synairgen is moving from the treatment of respiratory viral infections in patients with asthma to those with chronic obstructive pulmonary disease (COPD) with its inhaled interferon beta investigative therapy SNG001. The pharmaceutical company is planning a two-part trial of SNG001 to treat viral infections in COPD patients to take place this…
Verona Pharma’s lead investigational medicine RPL554, engineered to treat patients with chronic obstructive pulmonary disease (COPD) and other respiratory disorders, was found to have an effective therapeutic profile when administrated by inhalation to healthy volunteers. This finding resulted from data obtained during a U.S. clinical trial that Verona…
The U.S. Patent and Trademark Office (USPTO) issued two new patents requested by Pulmatrix – one for the expansion of its iSPERSE drug delivery technology and one for the expansion of protections for PUR0200, the company’s investigative candidate for chronic obstructive pulmonary disease (COPD). iSPERSE technology delivers drugs directly…
Two Phase 3 clinical trials demonstrated that the antibody Nucala (mepolizumab) from GlaxoSmithKline has a moderate efficacy in the reduction of the rate of exacerbations in chronic obstructive pulmonary disease (COPD) patients. The almost 20 percent decrease in the exacerbation rate was only observed in COPD patients with high levels of…
The U.S. Food and Drug Administration has approved a triple combination treatment developed by GlaxoSmithKline as a maintenance therapy for chronic obstructive pulmonary disease. GSK collaborated with Innoviva on the COPD combo, which consists of fluticasone furoate, umeclidinium and vilanterol. The approval means the once-a-day, single-inhaler therapy will enter the U.S. market under the brand…
Chiesi recently completed a long-term study showing that its extra-fine, fixed-dose, triple combination inhaler Trimbow is more effective than Utibron (indacaterol and glycopyrronium) as a therapy for chronic obstructive pulmonary disease (COPD). Trimbow contains the anti-inflammatory inhaled corticosteroid (ICS) beclomethasone dipropionate and two bronchodilators, the long-acting beta2 agonist (LABA) formoterol fumarate and the…
A triple combination inhaler for people with moderate to severe adult chronic obstructive pulmonary disease (COPD) was recommended for approval and use across the European Union this week by CHMP, the scientific arm of the European Medicines Agency’s (EMA). CHMP’s official name is the Committee for Medicinal Products for Human Use.
A combination of Verona Pharma’s COPD therapy candidate RPL554 and Spiriva (tiotropium) significantly improved patients’ lung function and appeared to ease their breathing difficulties, Phase 2a clinical trial results showed. The double-blind, placebo-controlled study (NCT03028142) looked at the combo’s ability to benefit 30 people with chronic obstructive pulmonary disease. Patients received…
Get regular updates to your inbox.